Fig. 4From: Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of 18F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-AgROC curve for predicting EGFR mutation status in male NSCLC patients using pSUVmax and serum tumor markers CYFAR21-1 and SCC-Ag. When pSUVmax, serum CYFAR21-1 and SCC-Ag concentrations were combined to predict EGFR mutation status, the AUC was 0.754Back to article page